Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Cardiac Electrophysiology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Sudden death in the young: what do we know about it and how to prevent?.Circ Arrhythm Electrophysiol. 2010; 3: 96-104
- Prevalence of the congenital long-QT syndrome.Circulation. 2009; 120: 1761-1767
- About Brugada syndrome and its prevalence.Europace. 2012; 14: 925-928
- A clinical approach to inherited arrhythmias.Circ Cardiovasc Genet. 2012; 5: 581-590
- Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing.J Am Coll Cardiol. 2012; 60: 1410-1418
- A sodium-channel mutation causes isolated cardiac conduction disease.Nature. 2001; 409: 1043-1047
- Founder mutations in the Netherlands. SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best described characterised families worldwide.Neth Heart J. 2009; 17: 422-428
- Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).Heart Rhythm. 2009; 6: 1335-1341
- Assessing cardiovascular drug safety for clinical decision-making. Nature reviews.Cardiology. 2013; 10: 330-337
- Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics.Europace. 2013; 15: 1042-1049
- Long QT syndrome in adults.J Am Coll Cardiol. 2007; 49: 329-337
- Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.Circulation. 2000; 102: 1178-1185
- Yield of molecular and clinical testing for arrhythmia syndromes: report of 15 years’ experience.Circulation. 2013; 128: 1513-1521
- Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy.J Am Coll Cardiol. 2009; 54: 832-837
- Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype.Circulation. 2005; 111: 2720-2726
- IK1 modulates the U-wave: insights in a 100 year old enigma.Heart Rhythm. 2009; 6: 393-400
- Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one.Heart Rhythm. 2005; 2: 569-574
- Accurate electrocardiographic assessment of the QT-interval: teach the tangent.Heart Rhythm. 2008; 5: 1015-1018
- The measurement of the QT interval.Curr Cardiol Rev. 2014; 10: 287-294
- Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families.Circulation. 2000; 102: 2509-2515
- Low penetrance in the long-QT syndrome: clinical impact.Circulation. 1999; 99: 529-533
- The response of the QT-interval to the brief tachycardia provoked by standing. A bedside test for diagnosing Long-QT syndrome.J Am Coll Cardiol. 2010; 55: 1955-1961
- Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands.Circulation. 2011; 124: 2187-2194
- The phenomenon of “QT stunning”: the abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome.Heart Rhythm. 2012; 9: 901-908
- Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER).Circulation. 2009; 120: 278-285
- Variants in the 3’ untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner.Eur Heart J. 2012; 33: 714-723
- Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.Nat Genet. 2013; 45: 1409
- Exercise extreme caution when calling rare genetic variants novel arrhythmia syndrome susceptibility mutations.Heart Rhythm. 2010; 7: 1883-1885
- The pathophysiological mechanism underlying Brugada syndrome. Depolarization versus repolarization.J Mol Cell Cardiol. 2010; 49: 543-553
- Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome.J Cardiovasc Electrophysiol. 2004; 15: 667-673
- A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification.Eur Heart J. 2006; 27: 2544-2554
- SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome.Circ Cardiovasc Genet. 2009; 2: 552-557
- Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death.Heart Rhythm. 2004; 1: 610-615
- Fever-induced life-threatening arrhythmias in children harboring an SCN5A mutation.Pediatrics. 2011; 127: e239-e244
- Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans.J Clin Invest. 2008; 118: 2260-2268
- A single Na(+) channel mutation causing both long-QT and Brugada syndromes.Circ Res. 1999; 85: 1206-1213
- Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel.Circ Res. 2000; 86: E91-E97
- The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.J Clin Invest. 2008; 118: 2219-2229
- Drug-induced prolongation of the QT interval.N Engl J Med. 2004; 350: 1013-1022
- Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts.Circulation. 2000; 101: 510-515
- Open- and closed-state fast inactivation in sodium channels: differential effects of a site-3 anemone toxin.Channels (Austin). 2011; 5: 65-78
- Slow delayed rectifier potassium current blockade contributes importantly to drug-induced Long QT syndrome.Circ Arrhythm Electrophysiol. 2013; 6: 1002-1009
- Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol.J Am Coll Cardiol. 2012; 60: 2092-2099
- Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.Medicine (Baltimore). 2003; 82: 282-290
- Ageing and Brugada syndrome: considerations and recommendations.J Geriatr Cardiol. 2013; 10: 75-81
- HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes expert consensus statement on inherited primary arrhythmia syndromes.Heart Rhythm. 2013; 10: 1932-1963
- Institution-wide QT alert system identifies patients with a high risk of mortality.Mayo Clin Proc. 2013; 88: 315-325
- Monitoring the safety of antiepileptic medication in a child with Brugada syndrome.Int J Cardiol. 2010; 145: e64-e67
- Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome.Circulation. 2008; 117: 2184-2191
- Long-QT syndrome after age 40.Circulation. 2008; 117: 2192-2201
- Sodium channel mutations, risk of cardiac events, and efficacy of beta-blocker therapy in type 3 Long QT syndrome.Heart Rhythm. 2012; 9 ([abstract]): S321
- Diurnal variation of ventricular repolarization in a large family with LQT3-Brugada syndrome characterized by nocturnal sudden death.Heart Rhythm. 2006; 3: 290-295
- Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome.J Cardiovasc Electrophysiol. 2001; 12: 630-636
- Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.Circulation. 1995; 92: 3381-3386
- Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review.Heart Rhythm. 2012; 9: 1995-2000
- Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries.J Am Coll Cardiol. 2013; 61: 2383-2387
- Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry.Heart Rhythm. 2009; 6: 401-404
Article info
Publication history
Published online: September 06, 2014
Footnotes
Conflicts of Interest: None.
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
